REVB Insider Trading

Insider Ownership Percentage: 1.40%
Insider Buying (Last 12 Months): $30,728.40
Insider Selling (Last 12 Months): $34,582.50

Revelation Biosciences Insider Trading History Chart

This chart shows the insider buying and selling history at Revelation Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Revelation Biosciences Share Price & Price History

Current Price: $2.43
Price Change: Price Decrease of -0.17 (-6.54%)
As of 03/27/2024 01:00 AM ET

This chart shows the closing price history over time for REVB up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Revelation Biosciences Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/8/2023George F. TidmarshDirectorSell925$15.60$14,430.00View SEC Filing Icon  
10/16/2023George F TidmarshDirectorSell365$19.80$7,227.001,403View SEC Filing Icon  
9/28/2023George F TidmarshDirectorSell47$20.70$972.901,403View SEC Filing Icon  
9/18/2023George F TidmarshDirectorSell133$22.20$2,952.601,311View SEC Filing Icon  
9/14/2023George F TidmarshDirectorSell400$22.50$9,000.001,761View SEC Filing Icon  
4/17/2023George F TidmarshDirectorBuy883$34.80$30,728.401,328View SEC Filing Icon  
2/25/2022George F TidmarshDirectorBuy19$1,680.00$31,920.00View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Revelation Biosciences (NASDAQ:REVB)

12.80% of Revelation Biosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at REVB by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Revelation Biosciences Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/21/2023Walleye Capital LLC391,355$0.27M0.0%+26.6%6.215%Search for SEC Filing on Google Icon
11/15/2023Sabby Management LLC403,233$0.28M0.2%+14.2%6.401%Search for SEC Filing on Google Icon
8/15/2023Walleye Capital LLC309,136$0.29M0.0%+77.0%5.110%Search for SEC Filing on Google Icon
7/27/2023Virtu Financial LLC66,972$63K0.0%N/A1.107%Search for SEC Filing on Google Icon
5/19/2023Anson Funds Management LP213,509$0.28M0.0%N/A3.700%Search for SEC Filing on Google Icon
5/16/2023Hudson Bay Capital Management LP109,520$0.14M0.0%N/A1.897%Search for SEC Filing on Google Icon
5/16/2023CVI Holdings LLC33,204$43K0.0%N/A0.575%Search for SEC Filing on Google Icon
5/16/2023Sabby Management LLC180,431$0.24M0.2%N/A3.125%Search for SEC Filing on Google Icon
5/16/2023Altium Capital Management LP37,198$48K0.0%N/A0.644%Search for SEC Filing on Google Icon
5/15/2023Anson Funds Management LP213,509$0.28M0.0%N/A3.698%Search for SEC Filing on Google Icon
5/15/2023AXA S.A.55,971$73K0.0%-97.1%0.969%Search for SEC Filing on Google Icon
11/15/2022State Street Corp108,828$28K0.0%N/A0.462%Search for SEC Filing on Google Icon
5/13/2022Ergoteles LLC22,327$25K0.0%N/A0.148%Search for SEC Filing on Google Icon
5/12/2022Monashee Investment Management LLC817,562$0.93M0.3%N/A5.420%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Revelation Biosciences logo
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, urinary tract infection, sepsis, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease. It is also developing REVTx-99b, a treatment for food allergies; REVTx-99a, an anti-viral nasal drop solution for the potential prevention or treatment of respiratory viral infection; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, influenza A, influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
Read More on Revelation Biosciences

Today's Range

Now: $2.43
Low: $2.36
High: $2.62

50 Day Range

MA: $4.54
Low: $2.28
High: $12.99

52 Week Range

Now: $2.43
Low: $2.22
High: $49.80

Volume

87,457 shs

Average Volume

224,323 shs

Market Capitalization

$510,300.00

P/E Ratio

0.08

Dividend Yield

N/A

Beta

0.14

Who are the company insiders with the largest holdings of Revelation Biosciences?

Revelation Biosciences' top insider investors include:
  1. George F Tidmarsh (Director)
  2. George F Tidmarsh (Director)
Learn More about top insider investors at Revelation Biosciences.